Bottom Line Three independent 2026 surveys agree on the direction, even though they report different numbers: employer coverage of GLP-1 medications for weight loss is retrenching, not expanding, as the drugs’ cost collides with the size of the eligible population. Several large, recognizable employers have dropped or are dropping coverage this year. For patients whose
Bottom Line A large real-world study published in January 2026 found that people with type 2 diabetes on tirzepatide had a lower rate of newly diagnosed dementia over two years than people on semaglutide or on SGLT2 inhibitors, and that semaglutide also outperformed SGLT2 inhibitors. The differences are real and statistically significant, but this is
THIS WEEK IN 30 SECONDS New analyses add evidence that tirzepatide can improve several cardiometabolic risk markers at the same time; a separate three-year analysis suggests sustained improvement in predicted cardiovascular risk; and dermatology investigators report a mix of improved inflammatory skin symptoms and more frequent cosmetic changes with larger weight loss. 1. Tirzepatide:
One of the most important questions in obesity medicine is whether losing weight with newer medications translates into better long-term cardiovascular health. An August 2026 analysis of three-year SURMOUNT-1 data provides encouraging evidence for tirzepatide – but the distinction between predicted risk and actual cardiovascular events is essential. What researchers studied SURMOUNT-1 was a randomized
When patients start tirzepatide (Zepbound) for obesity, the number on the scale is usually the most visible outcome. But obesity treatment is ultimately about health, not simply weight. A newly published analysis from the SURMOUNT clinical-trial program asks a useful question: how often do patients improve several important cardiometabolic measures at the same time? What
1. Orforglipron after Wegovy or Zepbound. ATTAIN-MAINTAIN found that patients transitioned from tirzepatide or semaglutide to oral orforglipron (Foundayo) maintained substantially more of their prior weight reduction than patients switched to placebo. A new option in the maintenance discussion. https://belite.com/orforglipron-maintenance-after-wegovy-zepbound/ 2. CagriSema vs. Zepbound. CagriSema delivered 23% average weight loss in its head-to-head trial —
